References
- Postma MJ. Public health aspects of vaccines in The Netherlands: methodological issues and applications. J. Public Health16, 267–273 (2008).
- Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin. Ther.9, 1651–1661 (2010).
- Trusheim MR, Berndt ER, Douglas FL. Stratified medicine and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6, 287–293 (2007).
- Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics22, 481–493 (2004).
- Boersma C, Broere A, Postma MJ. Quantification of the potential impact of cost–effectiveness thresholds on dutch drug expenditures using retrospective analysis. Value Health13, 853–856 (2010).
- Tolley K, Postma MJ. Pharmacoeconomics and market access in Europe: case studies in Scotland and The Netherlands. ISPOR Connections6(10), 3–6 (2006).
- Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: Stepping forward towards optimal decision rules. Health Econ.16, 307–317 (2007).
- Hoomans T, van der Roer N, Severens JL, Delwel GO. Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement(article in Dutch). Ned. Tijdschr. Geneeskd.154, A958 (2010).
- Vegter S, Boersma C, Rozenbaum M, Wilffert B, Navis G, Postma MJ. Pharmacoeconomic evaluation of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics26, 569–587 (2008).
- Vegter S, Jansen E, Postma MJ, Boersma C. Pharmacoeconomic evaluation of pharmacogenetic and genomic screening programs: an update of the literature. Drug Dev. Res.71, 492–501 (2010).
- Retèl VP, Hummel MJM, van de Vijver MJ et al. Constructive technology assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics. Int. J. Technol. Assess. Healthcare25, 73–83 (2009).
- Polonsky WH, Fisher L, Schikman CH et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated Type 2 diabetes. Diabetes Care34, 262–267 (2011).
Websites
- Pharmacoeconomic Guidelines Around The World www.ispor.org/PEguidelines/index.asp
- EUnetHTA Joint Action – new phase in EUnetHTA development www.eunethta.net